Trial Profile
The efficacy and safety of Apatinib as Neoadjuvant Therapy in locally advanced differentiated thyroid carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 20 Nov 2017 New trial record